The [۶۸Ga]Ga-DOTATATE and [۱۸F]FDG PET-CT imaging characteristics of metastatic neuroendocrine tumors
Publish place: Iranian Journal of Nuclear Medicine، Vol: 32، Issue: 2
Publish Year: 1403
نوع سند: مقاله ژورنالی
زبان: English
View: 32
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IRJNM-32-2_003
تاریخ نمایه سازی: 17 تیر 1403
Abstract:
Introduction: The [۶۸Ga]Ga-DOTA-conjugated somatostatin receptor imaging (SR) is becoming the standard imaging procedure in the management of the neuroendocrine tumors (NET). Meanwhile [۱۸F]FDG PET-CT as an adjunctive tool provides useful information in the imaging of NETs. The aim of this study was to compare the diagnostic utility of these imaging methods as well as demonstrate uptake characteristics of NETs.Methods: ۴۱ patients (۱۷ M, ۲۱ F; mean: ۵۷.۱ years old) with the diagnosis of metastatic neuroendocrine tumors were included in the study. [۱۸F]FDG PET-CT and/or [۶۸Ga]Ga-DOTATATE PET-CT imaging was performed in patients for initial staging, restaging, treatment response evaluation, lesion characterization or to find an unknown primary tumor. The results of the patients were compared with oncologic follow up results and/or pathology results.Results: The size of the lesions were mean: ۳۴ mm and the standardized uptake value in [۱۸F]FDG PET/CT SUVmax(F) and SUV in [۶۸Ga]Ga-DOTATATE PET/CT SUVmax(G) of the lesions were mean: ۱۰.۶ and ۳۲.۴ respectively. According to the follow up results of the ۲۳ patients with available initial and follow up imaging studies; the management of seven patients were changed (۳۰%). Among the NET group grade ۱-۳ tumors SUVmax(F) and SUVmax(G) levels were not significantly different.Conclusion: Diagnostic workup of metastatic NET’s should include either or both of the [۶۸Ga] DOTATATE and [۱۸F]FDG PET-CT imaging studies. Individualization of the imaging method of choice in every single patient would be an appropriate approach.
Keywords:
Authors
Zehra Pınar Koç
Nuclear Medicine Department, Faculty of Medicine, Mersin University, Mersin, Turkey
Pınar Pelin Özcan
Nuclear Medicine Department, Faculty of Medicine, Mersin University, Mersin, Turkey
Vehbi Erçolak
Oncology Department, Faculty of Medicine, Mersin University, Mersin, Turkey
Tuba Kara
Pathology Department, Faculty of Medicine, Mersin University, Mersin, Turkey
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :